Brokerages Set Integra LifeSciences Holdings Co. (NASDAQ:IART) Target Price at $23.00

Integra LifeSciences Holdings Co. (NASDAQ:IART) has been given a consensus rating of “Reduce” by the nine analysts that are presently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $23.00.

Separately, Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Monday.

Integra LifeSciences Trading Up 0.8 %

Shares of NASDAQ:IART opened at $21.78 on Monday. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The business’s 50 day moving average price is $23.61 and its 200-day moving average price is $22.27. The firm has a market capitalization of $1.68 billion, a price-to-earnings ratio of -241.97, a price-to-earnings-growth ratio of 0.73 and a beta of 1.23. Integra LifeSciences has a 1 year low of $16.81 and a 1 year high of $34.80.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $442.65 million during the quarter, compared to the consensus estimate of $445.15 million. During the same period in the prior year, the company earned $0.89 EPS. The firm’s revenue was up 11.5% compared to the same quarter last year. On average, equities research analysts forecast that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

A number of institutional investors and hedge funds have recently made changes to their positions in IART. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Integra LifeSciences in the fourth quarter valued at $1,721,000. Paradigm Capital Management Inc. NY raised its position in shares of Integra LifeSciences by 170.3% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company’s stock worth $32,457,000 after acquiring an additional 901,600 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Integra LifeSciences by 16.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 198,642 shares of the life sciences company’s stock worth $4,505,000 after purchasing an additional 28,457 shares during the last quarter. Woodline Partners LP acquired a new position in Integra LifeSciences in the fourth quarter valued at approximately $2,512,000. Finally, Soleus Capital Management L.P. purchased a new position in Integra LifeSciences in the fourth quarter valued at approximately $28,940,000. 84.78% of the stock is owned by institutional investors and hedge funds.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.